Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merck Sharp & Dohme LLC
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must be 18 to 75 years of age
Type 2 Diabetes Mellitus (Glycohemoglobin \[A1CHbA1c\]: 7 to 10%)
Hypertension: Diastolic blood pressure (DBP; 85 to 99 mm Hg) and systolic blood pressure (SBP; 120 to 159 mm Hg)
LDL-C \< 140 mg/dL
On stable treatment with an Angiotensin-Converting Enzyme Inhibitor (ACEI) or Angiotensin Receptor Blocker (ARB)
You may not be if
History of Type I Diabetes mellitus or ketoacidosis
Patients taking 3 or more blood pressure lowering medications
Have severe chronic heart failure
History of certain diseases or conditions such as cardiac arrhythmias, heart attack, stroke, unstable angina, or decompensated vascular disease
History of cancer within the last 5 years
Human immunodeficiency virus (HIV) Positive
Have received treatment with any investigational drugs within the past 30 days
History of alcohol or drug abuse within the past 3 years
Body Mass Index ( BMI) \>= 41 kg/m2
Clareo Health | Dose-ranging Study to Evaluate the Effectiveness and Tolerability of MK0736 in Patients With Type 2 Diabetes Mellitus (T2DM) and Hypertension (0736-007)
